IRWD - NASDAQ
Ironwood Pharmaceuticals, Inc.
$3.24
-1.2%Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotIronwood Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Ironwood Pharmaceuticals, Inc. Cash Flow Statement
IRWD • NASDAQ
| Ironwood Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
24M | 880K | -1B | 175.1M | 528.4M | 106.2M | 21.5M | -282.4M | -116.9M | -81.7M | -142.7M | -189.6M | -272.8M | -72.6M | -64.9M | -56.4M | -73.3M | -55M | -53.2M | -37.2M | |
1.9M | 2M | 1.6M | 1.4M | 1.5M | 3.6M | 5.6M | 14.2M | 14.6M | 11.3M | 11.6M | 12.3M | 11.7M | 11.3M | 10M | 6.2M | 5.3M | 2.8M | 1.7M | 1.3M | |
40.8M | 68.1M | 72.6M | 65.7M | -333.3M | 6.6M | 35.9M | 159.1M | 7.5M | -7.3M | 28.5M | 21.5M | 1.9M | 0.0 | 7K | -5.5M | 970K | -1K | -1K | 0.0 | |
17.3M | 29.9M | 32M | 27M | 22.3M | 31.2M | 31.3M | 44M | 33.8M | 29.2M | 25.5M | 26.2M | 19.8M | 17.6M | 11.7M | 7.5M | 5.2M | 2.8M | 1.2M | 0.0 | |
3.4M | 2M | 1.1B | 1.7M | 25.2M | 22.3M | 16.4M | -13.4M | -16.8M | 28.1M | 8.4M | 4.1M | 1.7M | 1.2M | 2.2M | 1.6M | -360K | 532K | -1.7M | 249K | |
(0.0) | (8.4M) | (9.9M) | (4.6M) | (3.5M) | (1.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3K | (0.0) | (153K) | (0.0) | (0.0) | (0.0) | |
39.7M | 739K | 11.3M | 2.8M | 17.7M | -941K | -100M | 7.6M | -21.8M | -5M | -38.2M | -30.1M | -35.7M | -27.1M | -34.4M | -21.3M | 58.2M | 20.7M | 45.2M | 2.1M | |
127M | 103.5M | 183.4M | 273.8M | 261.9M | 168.8M | 10.7M | -70.9M | -99.6M | -25.4M | -106.9M | -155.6M | -273.4M | -69.6M | -75.2M | -67.9M | -4M | -28.2M | -6.8M | -33.5M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-34K | -142K | -273K | -136K | -265K | -1.8M | -7.2M | -8.6M | -4.2M | -104.2M | -4M | -3.5M | -9.6M | -14M | -9.7M | -17.2M | -4M | -22.9M | -2.7M | -2.8M | |
(0.0) | (0.0) | -1B | (0.0) | (0.0) | (0.0) | (268K) | (1.6M) | (135K) | (100M) | (147K) | (0.0) | (0.0) | (0.0) | (0.0) | (9.5M) | (0.0) | (0.0) | (0.0) | (1K) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.2M | -191.4M | -311.1M | -282M | -254M | -287.9M | -96.7M | -97.5M | -441.8M | -26.7M | -82.6M | -87.8M | -37M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 99.2M | 346.9M | 237.4M | 276.7M | 201M | 196.1M | 140.8M | 222.3M | 236.5M | 48.5M | 90.5M | 62.9M | 34.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.2M | 1.6M | 135K | -99.8M | 147K | -53M | -91.8M | 9K | 4K | 2K | 21K | 9K | 1K | 0.0 | |
-34K | -142K | -1B | -136K | -265K | -1.8M | -11.1M | (88.9M) | (151.5M) | -177.7M | -9.2M | -56.6M | -101.4M | (30.1M) | (115.1M) | -213M | (17.8M) | -15.1M | -27.6M | -5.6M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
216K | 11M | 6.4M | -126.4M | -24.1M | 18.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 190.4M | 137.8M | 85.2M | 0.0 | 203.2M | 0.0 | 0.0 | 0.0 | 75M | |
0.0 | -115M | 300M | -120.7M | 0.0 | 0.0 | 7.2M | -1.8M | 8.8M | -28.8M | 321.7M | -2.2M | 174.2M | -275K | -260K | -2M | 1.1M | -1.2M | 720K | -1.9M | |
(0.0) | (0.0) | (0.0) | -126.4M | -24.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | -3M | -29.2M | 9.5M | 19.6M | 0.0 | -8.4M | 31.9M | 11.1M | 24.6M | -18.6M | 22.7M | 1.6M | 4M | 3.4M | 1.7M | 272K | 180K | 47K | 7M | |
216K | -107M | 277.2M | -237.6M | -4.6M | 18.5M | -1.2M | 30.1M | 19.8M | -4.2M | 303.1M | 210.9M | 313.6M | 89M | 3.1M | 203M | 41.7M | 48.6M | 50.7M | 80.1M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
-329K | -32K | -53K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
126.9M | -3.6M | -565.8M | 36.1M | 257.1M | 185.5M | -1.6M | 48.1M | 71.7M | -207.3M | 187M | -1.2M | -61.2M | 49.4M | 43M | -78M | 55.4M | 5.3M | 16.4M | 0.0 | |
88.6M | 92.2M | 657.9M | 621.9M | 364.8M | 179.2M | 180.8M | 132.8M | 54M | 261.3M | 74.3M | 75.5M | 136.7M | 87.3M | 44.3M | 122.3M | 67.7M | 62.4M | 46.1M | 0.0 | |
215.5M | 88.6M | 92.2M | 657.9M | 621.9M | 364.8M | 179.2M | 180.8M | 125.7M | 54M | 261.3M | 74.3M | 75.5M | 136.7M | 87.3M | 44.3M | 123.1M | 67.7M | 62.4M | 0.0 | |
127M | 103.4M | 183.2M | 273.6M | 261.6M | 167M | 3.5M | -79.5M | -103.8M | -129.6M | -111M | -159.1M | -282.9M | -83.6M | -84.9M | -85.1M | -8M | -51.1M | -9.4M | -36.4M |
SEC Filings
IRWD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K/A 8-K/A 2026 (Amended) N/A | May 21, 2026 | May 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 08, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 02, 2026 | January 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 18, 2025 | 2025 |
Related Guides
Continue your IRWD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.